Abstract: Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.
Type:
Application
Filed:
February 28, 2007
Publication date:
March 4, 2010
Applicant:
CENTRO DE INGENÍERA GENÉTICA Y BIOTECNOLOGÍA
Inventors:
Rolando Eduardo Rodriguez Fernandez, Ania De La Nuez Veulens, Mario Pablo Estrada Garcia, Rebeca Martinez Rodriguez, Glay Chinea Santiago, Osvaldo Reyes Acosta, Julio Raul Fernandez Masso, Diana Garcia Del Barco Herrera, Jorge Amador Berlanga Acosta, Alexis Musacchio Lasa
Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonspecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.
Type:
Grant
Filed:
February 13, 2007
Date of Patent:
July 28, 2009
Assignee:
Centro de Ingeniera Genetica y Biotecnologia
Inventors:
Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
Abstract: The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favouring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrisation of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine.
Type:
Grant
Filed:
December 4, 2002
Date of Patent:
December 16, 2008
Assignee:
Centro de Ingeniera Genetica y Biotecnologia
Inventors:
Jorge Berlanga Acosta, José I Fernández Montequin, Calixto Valdés Pérez, Neobalis Franco Pérez, Ingrid Rojas Constantin, Héctor Santana Milián, Larissa Chacón Corvea, Gerardo E. Guillén Nieto, Luis Herrera Martínez, Leonardo Canan-Haden Frías, Haydee Gerónimo Pérez, Jorge Sotolongo Pena